US FDA approves Medtronic's system for heart condition
Send a link to a friend
[December 14, 2023]
(Reuters) -Medtronic said on Wednesday that the U.S. Food and
Drug Administration (FDA) had approved its system for a type of
condition that can cause stroke or heart failure.
The system, PulseSelect Pulsed Field Ablation (PFA), is used for the
treatment of atrial fibrillation (AF), a condition that is characterized
by an irregular rhythm of the heart.
PFA is used for ablation procedures that treat AF using small burns or
freezes to cause some scarring on the inside of the heart to help break
up the electrical signals that cause irregular heartbeats.
Commercialization of the PFA system will start in early 2024, the
company said.
(Reporting by Christy Santhosh; Editing by Maju Samuel)
[to top of second column]
|
Medtronic Plc logo is seen displayed in this illustration taken,
April 10, 2023. REUTERS/Dado Ruvic/Illustration/File Photo
[© 2023 Thomson Reuters. All rights
reserved.]This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |